Click on a field for details on how to access that data via Web API, Excel, or CSV File Download.
| Open Price | |
| High Price | |
| Low Price | |
| Close Price | |
| Change | |
| Percent Change | |
| Volume |
| Avg Daily Volume | N/A |
| 52 Week High | $3.00 |
| 52 Week Low | $0.32 |
| Target Price | $5.00 |
| Ticker | ADIL:UW |
| Composite Ticker | ADIL:US |
| Security Name | Adial Pharmaceuticals Inc |
| Type | Ordinary Shares |
| Class | ADIL |
| Currency | USD |
| Round Lot Size | N/A |
| Primary | Yes |
| Delisted | No |
| ETF | No |
| Market Category | Common Stock |
| Market Sector | Equity |
| Exchange Symbol | ^USCOMP |
| Exchange Name | US COMPOSITE |
| Exchange City | N/A |
| Exchange Country | UNITED STATES OF AMERICA |
| Exchange Website | N/A |
| FIGI | BBG00HNGDV35 |
| Composite FIGI | BBG00HNGDTR4 |
| Share Class FIGI | BBG00HNGDTS3 |
| FIGI Unique ID | N/A |
| Dividend | N/A |
| Dividend Rate | N/A |
| Trailing Dividend Yield | 0.00% |
| 5-year Average Dividend Yield | 0.00% |
| Dividend Ex Date | 2023-08-07 |
| Beta | 0.6677 |
| 1-year beta | 0.8769 |
| 3-year beta | 0.6677 |
| 5-year beta | 0.9084 |
| 7-year beta | 1.3601 |
| 10-year beta | 1.3601 |
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
